Mymd Pharmaceuticals (NASDAQ:QCLS) Posts Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS) posted its quarterly earnings results on Wednesday. The company reported ($0.79) earnings per share for the quarter, Zacks reports.

Mymd Pharmaceuticals Stock Performance

QCLS remained flat at $2.89 during trading on Wednesday. The company had a trading volume of 48,502 shares, compared to its average volume of 674,812. Mymd Pharmaceuticals has a twelve month low of $2.50 and a twelve month high of $10.79. The company has a market capitalization of $12.04 million, a PE ratio of -0.14 and a beta of 2.16. The business’s 50-day simple moving average is $3.48.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wall Street Zen downgraded shares of Mymd Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Mymd Pharmaceuticals presently has a consensus rating of “Sell”.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.